21 recruiting, 16 not yet recruiting, 4 completed, 2 terminated. 18 Phase 2, 15 Phase 1, 3 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Diffuse Large B Cell Lymphoma (DLBCL): new trials by email Literature Review of Diffuse Large B Cell Lymphoma (DLBCL) trials Research Report on Diffuse Large B Cell Lymphoma (DLBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Prospective ctDNA Testing in Large B-Cell Lymphoma Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such as R-CHOP, Pola-R-CHP, or DA-EPOCH-R. - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Recruiting | Peking University People's Hospital | 100 | 2026-10-15 | 2026-10-16 | |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| Neurocognitive Assessment in Long-Term Survivors of Lymphoma anthracycline containing regimen - Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-09-01 | 2026-06-22 | |
| A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CART Infusion - Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma | Phase 2 | Not yet recruiting | Kure Cells, INC | 105 | 2026-08-31 | 2026-07-20 |
| A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 96 | 2026-07-22 | 2026-07-13 |
| Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Medical College of Wisconsin | 31 | 2026-06-01 | 2026-08-25 |
| Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas Vancomycin 125mg, Radiation Therapy, CAR-T - Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL) | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 14 | 2026-05-29 | 2026-07-01 |
| Proton Therapy for Mediastinal Lymphoma (PROMLY) Proton therapy - Mediastinal Lymphoma, Hodgkin Disease Lymphoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 139 | 2026-05-01 | 2026-09-14 |
| Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy Chimeric Antigen Receptor T-cells (CAR-T) therapy - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-05-01 | 2026-03-13 | |
| Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor - Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2026-04-01 | 2026-04-15 |
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 122 | 2026-02-28 | 2026-02-10 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion - Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL) | Early Phase 1 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 3 | 2025-12-31 | 2025-09-17 |
| Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy observational study - Diffuse Large B Cell Lymphoma (DLBCL) | Not yet recruiting | Peking Union Medical College Hospital | 200 | 2025-12-30 | 2025-12-30 | |
| Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma Zanubrutinib+Pola-R-CHP - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 50 | 2025-11-20 | 2026-01-28 |
| Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma Anbal-cel - Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Hyungwoo Cho | 12 | 2025-11-12 | 2025-12-17 |
Showing 20 of 46. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (46) · Lymphoma, Follicular (9) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, B-Cell (5) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Mantle-Cell (4) · Burkitt Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2) · Multiple Myeloma (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
Hemic and Lymphatic Diseases (46) · Immune System Diseases (46) · Immunoproliferative Disorders (46) · Lymphatic Diseases (46) · Lymphoproliferative Disorders (46) · Neoplasms by Histologic Type (46) · Neoplasms (44) · Lymphoma, B-Cell (41) · Lymphoma (39) · Lymphoma, Non-Hodgkin (39) · Hematologic Diseases (9) · Leukemia (8) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Disease Attributes (6)
Cyclophosphamide (5) · Doxorubicin (4) · glofitamab (4) · Prednisone (3) · Rituximab (3) · obinutuzumab (3) · Gemcitabine (2) · Oxaliplatin (2) · R-CHOP protocol (2) · orelabrutinib (2) · polatuzumab vedotin (2) · Epirubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1)
Fondazione Italiana Linfomi - ETS (4) · Ruijin Hospital (3) · Beijing Tongren Hospital (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Nurix Therapeutics, Inc. (2) · Sun Yat-sen University (2) · AbelZeta Inc. (1) · Abramson Cancer Center at Penn Medicine (1) · Andrés José Maria Ferreri (1) · Arcus Biosciences, Inc. (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Azienda USL Reggio Emilia - IRCCS (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Calibr, a division of Scripps Research (1) · Copenhagen University Hospital, Rigshospitalet (1)
United States (14) · China (12) · Italy (10) · Poland (3) · Spain (3) · United Kingdom (3) · Denmark (2) · France (2) · Netherlands (2) · South Korea (2) · Sweden (2) · Australia (1) · Bosnia and Herzegovina (1) · Canada (1) · Czechia (1)
Pier Luigi Zinzani, MD (2) · Carla Minoia, MD (1) · Djordje Atanackovic, MD (1) · Elise Chong, MD (1) · Francesco Merli, MD (1) · Hyungwoo Cho, Ph.D (1) · Jin Lu (1) · John Kuruvilla, FRCPC (1) · Liang Wang, M.D. (1) · Linda Neuman, MD (1) · Luca Castagna (1) · Luke Walker, MD (1) · Maria Elena Nizzoli, MD (1) · Marilena Bertini, MD (1)
PMID 21895543, PMID 29975624, PMID 34515338, PMID 35362047, PMID 36358694, PMID 36375120, PMID 41832699
2023 (2)